Skip to content

Study · Animal study (in vivo) · mouse · 2006

3 results

Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice.

Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA

Biochimica et biophysica acta13 Feb 2006Cited by 143 (Europe PMC)

PMID16503402 (opens in a new tab)DOI10.1016/j.bbadis.2006.01.008 (opens in a new tab)PepBankPUB-16503402
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In aged Tg 2576 mice, leuprolide attenuated cognitive decline compared with placebo.

    In plain wordsIn mice, leuprolide reduced cognitive decline compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseCognitive decline
    Study

    mousen: not reported in source

    aged Tg 2576 Alzheimer model
    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Our data indicate that luteinizing hormone ablation significantly attenuated cognitive decline and decreased amyloid-beta deposition as compared to placebo-treated animals.
    1 context sentence
    Summary · context
    we administered a gonadotropin-releasing hormone analogue, leuprolide acetate, to an aged transgenic mouse model of Alzheimer disease (Tg 2576) and measured cognitive Y-maze performance and amyloid-beta deposition after 3 months of treatment.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In aged Tg 2576 mice, leuprolide decreased amyloid-beta deposition compared with placebo.

    In plain wordsIn mice, leuprolide reduced brain amyloid-beta deposits compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreaseAmyloid-beta deposition
    Study

    mousen: not reported in source

    aged Tg 2576 Alzheimer model
    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Our data indicate that luteinizing hormone ablation significantly attenuated cognitive decline and decreased amyloid-beta deposition as compared to placebo-treated animals.
    1 context sentence
    Summary · context
    we administered a gonadotropin-releasing hormone analogue, leuprolide acetate, to an aged transgenic mouse model of Alzheimer disease (Tg 2576) and measured cognitive Y-maze performance and amyloid-beta deposition after 3 months of treatment.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In aged transgenic mice, leuprolide-mediated amyloid-beta reduction correlated with improved cognition.

    In plain wordsIn mice, reduced amyloid-beta during leuprolide treatment was linked to better cognition.

    Peptide
    Leuprolide
    Outcome
    Not applicableAmyloid-beta and cognition correlation
    Study

    mousen: not reported in source

    aged Tg 2576 Alzheimer model
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 3 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Importantly, leuprolide acetate-mediated reduction of amyloid-beta correlated with improved cognition.
    1 context sentence
    Summary · context
    we administered a gonadotropin-releasing hormone analogue, leuprolide acetate, to an aged transgenic mouse model of Alzheimer disease (Tg 2576) and measured cognitive Y-maze performance and amyloid-beta deposition after 3 months of treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.